Industry Overview

Oncolytic virus therapy market was valued at $178 million in 2025 and is projected to reach $716.6 million by 2035, growing at a CAGR of 6.2% during the forecast Period (2026-2035). The growth is driven by rising cancer incidence, significant R&D investment, positive clinical trial outcomes, and supportive regulatory environments, with key drivers including viral engineering, government funding, and combinations with other cancer treatments, while challenges include high costs and safety concerns. This dynamic market, focused on using modified viruses to kill cancer cells, sees major players like Amgen and Oncolytics Biotech leading, targeting cancers such as melanoma, prostate, and glioblastoma.

Market Dynamics

Rising Global Cancer Burden and Unmet Therapeutic Needs

A primary driver of growth in the oncolytic virus therapy market is the increasing global prevalence of cancer, especially aggressive and treatment?resistant forms that do not respond well to conventional therapies like chemotherapy and radiation. As the global incidence of various cancers continues to rise, the demand for innovative and effective treatment modalities has intensified. Oncolytic virus therapies offer a unique mechanism to selectively infect and destroy cancer cells and stimulate antitumor immunity, which addresses critical limitations in existing treatment options. This unmet clinical need has spurred investment, clinical development, and adoption of these therapies, particularly in regions with rising oncology burdens.

Advances in Viral Engineering and Combination Approaches

Technological progress in genetic engineering and virology is significantly driving market growth by enabling the development of more potent, selective, and safe oncolytic virus candidates. Innovations such as CRISPR?based editing, synthetic biology, and advanced viral vector design allow developers to enhance tumor specificity, optimize replication within cancer cells, and fine?tune immune activation. Additionally, oncolytic viruses are increasingly being investigated in combination with other cancer treatments such as immune checkpoint inhibitors and CAR?T therapies which has demonstrated synergistic effects in clinical research and expanded therapeutic potential. These scientific and technological advancements are attracting substantial R&D investments and collaborative efforts between biopharmaceutical companies and academic institutions.

Supportive Clinical and Regulatory Environment

The expansion of clinical research programs and a more supportive regulatory environment are boosting market momentum. Oncolytic virus therapies are a major focus of ongoing clinical trials worldwide, with increasing patient enrollment and diversified indications. Positive clinical outcomes and regulatory designations such as Fast Track and Orphan Drug status in major markets help facilitate accelerated development and reduce approval barriers for promising candidates. Such regulatory support enhances confidence among developers and investors, speeding up the progression of novel therapies through clinical pipelines and into commercialization. This favorable environment is a key driver of long?term growth for the oncolytic virus therapy landscape.

Market Segmentation

• Based on the product, the market is segmented into HSV-based oncolytic viruses, adenovirus-based oncolytic viruses, and others.
• Based on the application, the market is segmented into melanoma and others.

HSV-Based Oncolytic Viruses Segment to Grow at a Considerable Market Share

HSV-based oncolytic viruses emerge as the largest segment leading the global oncolytic virus therapy market. This dominance is primarily driven by the commercial success and widespread clinical adoption of Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic herpes simplex virus therapy for melanoma. HSV-based platforms offer several advantages, including high tumor specificity, robust immune activation, and the ability to carry therapeutic transgenes, which enhances antitumor efficacy.

Additionally, HSV-based therapies have demonstrated consistent safety and efficacy across multiple clinical trials, creating strong physician and patient confidence and establishing HSV viruses as the preferred platform in both monotherapy and combination therapy approaches. As a result, HSV-based oncolytic viruses capture the largest revenue share and continue to dominate the market landscape, outpacing adenovirus-based therapies and other emerging viral platforms, particularly in North America and Europe, where regulatory approvals and infrastructure support facilitate rapid adoption.

Melanoma: A Key Segment in Market Growth

Melanoma represents the most significant and fastest-growing segment in the global market. The strong growth is primarily attributed to the early clinical success and regulatory approval of talimogene laherparepvec (Imlygic), the first oncolytic virus therapy approved by the FDA for advanced melanoma. Melanoma is a highly aggressive form of skin cancer, and conventional therapies often show limited efficacy in late-stage or metastatic cases. Oncolytic virus therapies offer a dual mechanism of action for this segment: they directly lyse tumor cells and stimulate systemic antitumor immune responses, making them particularly effective for patients with unresectable or advanced melanoma.

Furthermore, the ongoing expansion of clinical trials investigating oncolytic viruses in combination with immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 therapies, has enhanced the therapeutic potential and adoption in melanoma treatment. North America, especially the United States, leads in melanoma-focused oncolytic virus therapy adoption due to high disease prevalence, supportive regulatory frameworks, and advanced healthcare infrastructure. The success in melanoma is also encouraging pipeline development for other tumor types, positioning this segment as the primary growth driver and a benchmark for market expansion globally.

Regional Outlook

The global oncolytic virus therapy market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US is the clear leader in the global oncolytic virus therapy market, driven by a combination of high disease prevalence, advanced healthcare infrastructure, and strong regulatory and investment support. The US accounts for the largest share of market revenue due to early adoption of oncolytic virus therapies such as talimogene laherparepvec (Imlygic), the first FDA-approved oncolytic virus for melanoma, and several investigational candidates in late-stage clinical trials. Extensive R&D activities by leading biopharmaceutical companies, including Amgen, Sorrento Therapeutics, Replimune, and Calidi Biotherapeutics, have been concentrated in the US, further consolidating its market dominance. Favorable government initiatives, expedited regulatory pathways such as Fast Track and Breakthrough Therapy designations, and high patient awareness contribute to faster adoption of innovative therapies.

Moreover, the country’s strong network of academic and research institutions supports translational research, enabling rapid commercialization of novel viral therapies. North America, led by the US also benefits from significant venture capital and private equity funding directed toward immunotherapy and oncology biotech startups, ensuring a continuous pipeline of next-generation oncolytic virus candidates. These factors collectively position the United States as the most influential and dominant market for oncolytic virus therapy globally, both in terms of revenue and innovation leadership.

Market Players Outlook

The major companies operating in the global oncolytic virus therapy market include Amgen Inc., Genelux Corp., Merck & Co., Inc., Oncolytics Biotech Inc., and Transgene SA, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In February 2025, Biotech firm UroGen Pharma acquired ICVB?1042, a next-generation oncolytic virus, from IconOVir Bio as part of its long-term growth strategy. Designed to selectively destroy cancer cells while stimulating immune responses, ICVB?1042 enhances UroGen’s bladder cancer pipeline via local administration.
• In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to ImmVira’s HSV-based therapy MVR?T3011, developed for recurrent or metastatic head and neck cancer following resistance to standard treatments. This milestone underscores the speed and seriousness with which regulatory bodies are treating oncolytic virus candidates in North America.
• In May 2024, Moffitt Cancer Center, collaborated with Duke Cancer Institute, initiated a first-in-human trial combining oncolytic virus MEM?288 with the PD?1 inhibitor nivolumab for patients with late-stage non–small-cell lung cancer (NSCLC) whose disease progressed after immunotherapy. MEM?288, an engineered adenovirus expressing IFN? and a membrane-stable CD40 ligand (MEM40), has demonstrated safety, tumor reduction, and enhanced T?cell activity in phase?

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global oncolytic virus therapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.